🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 100% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size
28 Servings
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

180 mcg (150% DV)
✅ 1.5× RDA — within safe limits 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.18mg

Other Ingredients

Microcrystalline Cellulose Starch, Pregelatinized Ascorbyl Palmitate Croscarmellose Sodium Silicon Dioxide Maltodextrin Sunflower Lecithin Palm Olein Guar Gum

Label Claims — Verification

All Other
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Directions: Take one (1) tablet daily, preferably with food.

⚠️ Warnings & Precautions

Keep out of reach of children.

Consult your physician if you are pregnant, nursing, taking a prescription drug, or have a medical condition.

There is a safety seal under the cap. Do not use if the seal is broken or missing.

🧪 Formulation Notes

Laboratory tested. Quality guaranteed. Meets USP specification for uniformity, potency, and disintegration, where applicable.

Additional Information

Keep tablets in original container with the lid tightly closed between use. Store in a cool, dry place. Store below 25 degrees C.

Discard seal, empty & replace cap Plastic bottle how2recycle.info

MWT Potency Guaranteed

Product Details

DSLD Entry Date 2024-12-21
Product Type Vitamin
Form Tablet or Pill
Brand USANA
DSLD ID 322337
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →